Toxin peptide therapeutic agents

US7833979B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• John K. Sullivan · Newbury Park, US
• Joseph G. McGivern · Mountain View, US
• Leslie P. Miranda · Thousand Oaks, US
• Hung Q. Nguyen · Thousand Oaks, US
• Kenneth W. Walker · Newbury Park, US
• Shaw-Fen Sylvia Hu · Thousand Oaks, US
• Colin Gegg · Newbury Park, US
• Stefan I. McDonough · San Francisco, US

Key dates

• Filing date: Apr 17, 2006
• Grant date: Nov 16, 2010
• Expiry date: Oct 5, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a composition of matter of the formula(X1)a—(F1)d—(X2)b—(F2)e—(X3)c  (I)and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthri…